rxraa Antibody

Immune Regulation

• T-Lymphocyte Function: Rxra knockout mice exhibited reduced T-cell proliferation, increased apoptosis, and a Th1 bias in cytokine production (e.g., elevated IFN-γ, reduced IL-5) .

• B-Lymphocyte Populations: Splenic B-cell percentages were lower in knockout mice, suggesting RXRA’s role in lymphocyte homeostasis .

Cancer Therapeutics

• Chronic Myeloid Leukemia (CML): RXRA overexpression (OE) in CML cell lines (e.g., Lama84) enhanced imatinib sensitivity by suppressing BCR-ABL signaling (p-CRKL, p-STAT5) and increasing apoptosis via caspase-3/PARP activation .

  • In Vivo Impact: RXRA OE reduced bone marrow engraftment and prolonged survival in murine models .

Transcriptional Regulation

• CCL2 Gene Modulation: RXRA and EGR1 cooperatively regulate CCL2 expression in response to TGF-β, influencing cancer cell migration and inflammation .

Validation Data

Recent Advances and Clinical Relevance

• Metabolic Regulation: RXRA/PPARA heterodimers drive fatty acid oxidation genes (e.g., ACOX1), linking RXRA to metabolic syndrome and diabetes .

• Neuroinflammation: RXRA promotes myelin phagocytosis in macrophages, suggesting therapeutic potential in demyelinating diseases .

Limitations and Future Directions

While RXRA antibodies are robust in research, discrepancies in observed molecular weights (e.g., 50–54 kDa vs. predicted 51 kDa) highlight batch variability . Future studies should explore isoform-specific antibodies and RXRA’s role in epigenetic regulation.